Advancing the development of tuberculosis therapy

ABSTRACT Although the development of novel drugs and combination regimens for tuberculosis has accelerated in recent years, the pipeline remains thin and major challenges remain to be

addressed in efficiently evaluating newer drugs to improve treatment outcomes, shorten duration of therapy and tackle drug resistance. Access through your institution Buy or subscribe This

is a preview of subscription content, access via your institution ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00

per year only $17.42 per issue Learn more Buy this article * Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated

during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * World Health Organization. Global

tuberculosis control 2011. _WHO website_ [online], (WHO, Geneva, Switzerland, 2011). * World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis:

2011 update. _WHO website_ [online], (WHO, Geneva, Switzerland, 2012). * Orenstein, E. W. et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review

and meta-analysis. _Lancet Infect. Dis._ 9, 153–161 (2009). Article  Google Scholar  * STOP TB Partnership. Working group on new TB drugs discovery portfolio. _New TB Drugs website_

[online], (2011). * Phillips, P. et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. _J. Infect. Dis._ (in the press). Download references

AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * Alimuddin Zumla is at the Division of Infection and Immunity, University College London, London NW3 2PF, UK., Alimuddin Zumla * Richard Hafner

is at the National Institute for Allergy and Infectious Diseases, US National Institutes of Health, Bethesda, Maryland 20892, USA., Richard Hafner * Christian Lienhardt is at the Stop TB

Partnership, 20 avenue Appia 1211, World Health Organization, Geneva 27, Switzerland., Christian Lienhardt * Michael Hoelscher is at the Division of Infectious Diseases and Tropical

Medicine, University of Munich, Leopoldstraße 5, 80802 Munich, Germany., Michael Hoelscher * Andrew Nunn is at the Medical Research Council, 222 Euston Road, London NW1 2DA, UK., Andrew Nunn

Authors * Alimuddin Zumla View author publications You can also search for this author inPubMed Google Scholar * Richard Hafner View author publications You can also search for this author

inPubMed Google Scholar * Christian Lienhardt View author publications You can also search for this author inPubMed Google Scholar * Michael Hoelscher View author publications You can also

search for this author inPubMed Google Scholar * Andrew Nunn View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to

Alimuddin Zumla. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing financial interests. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS

ARTICLE Zumla, A., Hafner, R., Lienhardt, C. _et al._ Advancing the development of tuberculosis therapy. _Nat Rev Drug Discov_ 11, 171–172 (2012). https://doi.org/10.1038/nrd3694 Download

citation * Published: 01 March 2012 * Issue Date: March 2012 * DOI: https://doi.org/10.1038/nrd3694 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this

content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative